» Articles » PMID: 32824946

Effect of Strain Variations on Lassa Virus Z Protein-Mediated Human RIG-I Inhibition

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2020 Aug 23
PMID 32824946
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Mammarenaviruses include several known human pathogens, such as the prototypic lymphocytic choriomeningitis virus (LCMV) that can cause neurological diseases and Lassa virus (LASV) that causes endemic hemorrhagic fever infection. LASV-infected patients show diverse clinical manifestations ranging from asymptomatic infection to hemorrhage, multi-organ failures and death, the mechanisms of which have not been well characterized. We have previously shown that the matrix protein Z of pathogenic arenaviruses, including LASV and LCMV, can strongly inhibit the ability of the innate immune protein RIG-I to suppress type I interferon (IFN-I) expression, which serves as a mechanism of viral immune evasion and virulence. Here, we show that Z proteins of diverse LASV isolates derived from rodents and humans have a high degree of sequence variations at their N- and C-terminal regions and produce variable degrees of inhibition of human RIG-I (hRIG-I) function in an established IFN-β promoter-driven luciferase (LUC) reporter assay. Additionally, we show that Z proteins of four known LCMV strains can also inhibit hRIG-I at variable degrees of efficiency. Collectively, our results confirm that Z proteins of pathogenic LASV and LCMV can inhibit hRIG-I and suggest that strain variations of the Z proteins can influence their efficiency to suppress host innate immunity that might contribute to viral virulence and disease heterogeneity.

Citing Articles

Lassa virus protein-protein interactions as mediators of Lassa fever pathogenesis.

Jan S, Phadke K, Lam V, Branda S, Johnson D Virol J. 2025; 22(1):52.

PMID: 40022100 PMC: 11869472. DOI: 10.1186/s12985-025-02669-y.


Pathogenic and Apathogenic Strains of Lymphocytic Choriomeningitis Virus Have Distinct Entry and Innate Immune Activation Pathways.

Johnson D, Khakhum N, Wang M, Warner N, Jokinen J, Comer J Viruses. 2024; 16(4).

PMID: 38675975 PMC: 11053560. DOI: 10.3390/v16040635.


Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines.

Murphy H, Ly H Vaccines (Basel). 2022; 10(10).

PMID: 36298533 PMC: 9612042. DOI: 10.3390/vaccines10101668.


Evaluating the Biological Role of Lassa Viral Z Protein-Mediated RIG-I Inhibition Using a Replication-Competent Trisegmented Pichinde Virus System in an Inducible RIG-IN Expression Cell Line.

Di D, Huang Q, Ly H, Liang Y J Virol. 2022; 96(16):e0075422.

PMID: 35913216 PMC: 9400496. DOI: 10.1128/jvi.00754-22.


Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

Salam A, Duvignaud A, Jaspard M, Malvy D, Carroll M, Tarning J PLoS Negl Trop Dis. 2022; 16(3):e0010289.

PMID: 35353804 PMC: 9000057. DOI: 10.1371/journal.pntd.0010289.


References
1.
Carnec X, Baize S, Reynard S, Diancourt L, Caro V, Tordo N . Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J Virol. 2011; 85(22):12093-7. PMC: 3209271. DOI: 10.1128/JVI.00429-11. View

2.
Meyer B, Ly H . Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses. J Virol. 2016; 90(8):3810-3818. PMC: 4810556. DOI: 10.1128/JVI.03049-15. View

3.
Perez M, Craven R, de la Torre J . The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A. 2003; 100(22):12978-83. PMC: 240730. DOI: 10.1073/pnas.2133782100. View

4.
McCormick J, Fisher-Hoch S . Lassa fever. Curr Top Microbiol Immunol. 2002; 262:75-109. DOI: 10.1007/978-3-642-56029-3_4. View

5.
Abdel-Hakeem M . Viruses Teaching Immunology: Role of LCMV Model and Human Viral Infections in Immunological Discoveries. Viruses. 2019; 11(2). PMC: 6410308. DOI: 10.3390/v11020106. View